Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression

L Léa Pechtimaldjian (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) M Marie-Laure Jullié (Service de Pathologie, Centre Hospitalier Universitaire de Bordeaux) C Chloé Rousson (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) F Faiza Laanani (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) J Julie Clachet (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) Y Yamina Idrissi (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) M Maya Loot (Service de Chirurgie Pédiatrique, Centre Hospitalier Universitaire de Bordeaux) M Muriel Cario-Andre (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) S Sorilla Prey (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) A Alain Taieb (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) C Christine Leauté-Labrèze (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) T Thomas Mathivet (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) F François Moisan (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312)

Abstract

The natural course of infantile hemangioma (IH), a benign vascular infantile tumor, is marked by the initial rapid proliferation of dystrophic capillaries, followed by a regression phase, which is either spontaneous or induced by the first line treatment propranolol. Although endothelial cells have been at the center of most studies, the role of stromal cells in this vascular remodeling has remained unclear. Telocytes, which are stromal cells that may be targeted by propranolol, are involved in tissue organization and angiogenesis, suggesting their role in vascular remodeling during the regression of IH. To assess changes in vascular architecture of IH and the role of telocytes, we used Skin-iDISCO + 3-Dimensions (3D) sample imaging and in vitro models with patient-derived telocytes. Perivascular telocytes exhibited increased dendricity during regression, indicating their activation. Telocytes secretome profiling revealed a complex inhibitory program, with pentraxin 3 (PTX3) emerging as a central effector. 3D multicellular disease models demonstrated a paracrine effect blocking endothelial fibroblast growth factor receptors (FGFR) signaling via FGF2–PTX3 interaction, thereby strongly regulating endothelial proliferation, sprouting, and activation. In vitro mechanistic study and collagen IV staining analysis revealed that vascular regression is at least partially due to vascular pruning. These findings highlight the pivotal role of telocytes in orchestrating vascular remodeling during IH regression, opening therapeutic perspectives for inducing vascular normalization in pathological angiogenesis, including cancer.

Article Details

Volume / Issue Vol. 123, Issue 24
Published June 16, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (13)

L

Léa Pechtimaldjian

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

M

Marie-Laure Jullié

Service de Pathologie, Centre Hospitalier Universitaire de Bordeaux

C

Chloé Rousson

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

F

Faiza Laanani

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

J

Julie Clachet

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

Y

Yamina Idrissi

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

M

Maya Loot

Service de Chirurgie Pédiatrique, Centre Hospitalier Universitaire de Bordeaux

M

Muriel Cario-Andre

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

S

Sorilla Prey

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

A

Alain Taieb

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

C

Christine Leauté-Labrèze

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

T

Thomas Mathivet

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

F

François Moisan

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312